This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2010 Remove Conflict of Interest Remove Ethics Remove Innovation
article thumbnail

Big Pharma's Hidden Business Model and How Your Company Funds It

Harvard Business Review

SEPTEMBER 12, 2012

Equating "innovative" with new molecules misses the point: to develop clinically superior new medicines. The apparent business model of Big Pharma emphasizes the billions spent at great risk to find "innovative" and "breakthrough" new molecules that must be priced high to recover research costs that have become "unsustainable."

Business Model 15
Business Model Company Pharmaceuticals Price 15
article thumbnail

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. Enhance corporate reputations.

Reputation 8
Reputation Pharmaceuticals Price Business Model 8
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024